Sign inJoin waitlistJoin the waitlist

Loretta Nastoupil

Physician · CommonSpirit Mountain Region

Credentials: · · · · · · · ·

History

CommonSpirit Mountain Region
2024–Present

Hematology & Medical Oncology
2012–2015
Emory University School of Medicine
2010–2012
Washington University/B-JH/SLCH Consortium
2007–2010
Univ of Texas Southwestern Med Sch at Dallas
2003–2007

Research

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 2,915 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Journal of Clinical Oncology · 2021 · 1,863 citations
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Journal of Clinical Oncology · 2020 · First of 28 authors · 691 citations

Christopher Flowers
117 papers
Sattva Neelapu
110 papers
Jason Westin
101 papers
Luis Fayad
85 papers
NF
Nathan Fowler
75 papers
Sairah Ahmed
59 papers
Paolo Strati
56 papers
FS
Felipe Samaniego
50 papers
Chelsea Pinnix
49 papers
Hun Lee
47 papers · 3 as a resident
Ranjit Nair
44 papers
Fredrick Hagemeister
43 papers

Clinical trials

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2017–2023
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2016–2024
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2016–2023
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2014–2023